Selective antitumor effect of neural stem cells expressing cytosine deaminase and interferon-beta against ductal breast cancer cells in cellular and xenograft models  by Yi, Bo-Rim et al.
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
ScienceDirect
www.e l sev i e r . com / l oca te / s c r
Stem Cell Research (2014) 12, 36–48Selective antitumor effect of neural stem
cells expressing cytosine deaminase and
interferon-beta against ductal breast cancer
cells in cellular and xenograft models
Bo-Rim Yi a, Kyung-A. Hwanga, Karen S. Aboodyb, Eui-Bae Jeunga,
Seung U. Kimc,d, Kyung-Chul Choi a,⁎a Laboratory of Veterinary Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University,
Cheongju, Chungbuk, Republic of Korea
b Department of Neurosciences and Neurosurgery, City of Hope National Medical Center and Beckman Research Institute,
Duarte, CA, USA
c Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
d Medical Research Institute, Chung-Ang University College of Medicine, Seoul, Republic of Korea
Received 29 December 2012; received in revised form 10 August 2013; accepted 23 September 2013
Available online 1 October 2013Abstract Due to their inherent tumor-tropic properties, genetically engineered stem cells may be advantageous for gene
therapy treatment of various human cancers, including brain, liver, ovarian, and prostate malignancies. In this study, we
employed human neural stem cells (HB1.F3; hNSCs) transduced with genes expressing Escherichia coli cytosine deaminase
(HB1.F3.CD) and human interferon-beta (HB1.F3.CD.IFN-β) as a treatment strategy for ductal breast cancer. CD can convert
the prodrug 5-fluorocytosine (5-FC) to its active chemotherapeutic form, 5-fluorouracil (5-FU), which induces a tumor-killing
effect through DNA synthesis inhibition. IFN-β also strongly inhibits tumor growth by the apoptotic process. RT-PCR confirmed
that HB1.F3.CD cells expressed CD and HB1.F3.CD.IFN-β cells expressed both CD and IFN-β. A modified transwell migration
assay showed that HB1.F3.CD and HB1.F3.CD.IFN-β cells selectively migrated toward MCF-7 and MDA-MB-231 human breast
cancer cells. In hNSC-breast cancer co-cultures the viability of breast cancer cells which were significantly reduced by
HB1.F3.CD or HB1.F3.CD.IFN-β cells in the presence of 5-FC. The tumor inhibitory effect was greater with the HB1.F3.CD.IFN-β
cells, indicating an additional effect of IFN-β to 5-FU. In addition, the tumor-tropic properties of these hNSCs were found to be
attributed to chemoattractant molecules secreted by breast cancer cells, including stem cell factor (SCF), c-kit, vascular
endothelial growth factor (VEGF), and VEGF receptor 2. An in vivo assay performed using MDA-MB-231/luc breast cancer
mammary fat pad xenografts in immunodeficient mice resulted in 50% reduced tumor growth and increased long-term survival⁎ Corresponding author at: Laboratory of Veterinary Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National
University, Cheongju, Chungbuk 361-763, Republic of Korea. Fax: +82 43 267 3150.
E-mail address: kchoi@cbu.ac.kr (K.-C. Choi).
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37Stem cell mediated therapy for breast cancerin HB1.F3.CD and HB1.F3.CD.IFN-β plus 5-FC treated mice relative to controls. Our results suggest that hNSCs genetically
modified to express CD and/or IFN-β genes can be used as a novel targeted cancer gene therapy.
© 2013 The Authors. Published by Elsevier B.V. Open access under the CC BY-NC-ND license.1. IntroductionMalignant breast cancer may present with symptoms that
include a change in breast size or shape, swelling, and/or
thickening within the breast tissue (Bevers et al., 2009). When
these symptoms are detected early, there is a better chance of
successful treatment by means of surgery, chemotherapy and/
or hormone therapy resulting in increased survival rates (Lv et
al., 2010). Histopathologically, breast cancers are classified
into two types depending on the area of origin: ductal and
lobular carcinomas. More than 80% of breast cancer cases are
ductal carcinoma originating from malignant epithelial cells
within the mammary ducts or tubes (Vincent-Salomon and
Thiery, 2003). Various risk factors that may be involved in the
development of breast cancer include gender, age, female
hormone exposure, family history, and genetic factors (Vogel
et al., 2007). Specifically, the high risk genes include breast
cancer types 1 and 2 susceptibility proteins (BRCA1 and
BRCA2), p53, phosphatase and tensin homolog (PTEN), and
cell cycle checkpoint kinase 2 (CHEK2) (Lynch et al., 2008).
These proteins encoded by BRCA1, BRCA2, p53, PTEN, and
CHEK2 genes are involved in control of cell cycle, proliferation,
differentiation, or DNA repair and apoptosis of somatic cells
(Lim et al., 2009; Wallace et al., 2011).
In this study, we investigated neural stem cell-directed
enzyme/prodrug therapy (NDEPT) or a suicide gene therapy
designed to more selectively target breast cancer cells and to
minimize toxicity to normal tissues (Yi et al., 2012). This
system induces cell death in tumor cells by the bystander
effect of a suicide enzyme which converts an inactive prodrug
into toxic metabolites (Hernandez-Alcoceba et al., 2006). One
NDEPT is the cytosine deaminase (CD)/5-fluorocytosine (5-FC)
system that has been applied to several types of cancers,
including clinical trials for colorectal and prostate cancers and
glioblastoma multiform (Fuchita et al., 2009). The CD
metabolically converts the prodrug 5-FC into the toxic
metabolite 5-fluorouracil (5-FU), which inhibits DNA synthesis
and induces apoptosis in cancer cells (Danks et al., 2007).
Specifically, cancer cell death results from the cytotoxic
activity of 5-fluoro-deoxyuridine-monophosphate (5FdUMP)
and 5-fluoro-deoxyuridine-triphosphate (5-FUTP), subse-
quently converted from 5-FU (Longley et al., 2003). Although
5-FU is a strong antitumor agent and used as chemotherapy for
breast, stomach, and colon cancer (Zoli et al., 2005), it has
several undesirable neurological and hematological side
effects including mucositis, abdominal cramps, vomiting,
and tiredness (Volate et al., 2009). Therefore, the develop-
ment of a more selective delivery system to target the gene
product to sites of tumor and not to normal tissues is urgently
needed for more effective gene therapy.
Genetically engineered stem cells may have an advantage
for gene therapy due to their inherent migration to tumor
sites (Kang et al., 2012a; Kang et al., 2012b; Kang et al.,
2012d). In this study, we employed HB1.F3 human neuralstem cells (hNSCs) obtained from 15 week fetal telenceph-
alon and immortalized using a retroviral vector encoding
v-myc, and cloned (Yi et al., 2011b). hNSCs have been shown
to effectively migrate to the target tumor site, drawn to
various chemokines and growth factors such as stem cell
factor (SCF), hepatocyte growth factor (HGF), vascular
endothelial growth factor (VEGF), and c-kit that are
secreted by proliferative by tumor cells (Aboody et al.,
2008). We used two NDEPT paradigms in our breast cancer
studies: 1) HB1.F3.CD expressing Escherichia coli CD and 2)
HB1.F3.CD.IFN-β additionally expressing human IFN-β (Yi et
al., 2011a). We previously showed that HB1.F3.CD or
HB1.F3.CE (carboxylesterase) cells significantly inhibit the
growth of SKOV-3 human ovarian cancer cells in the
presence of the prodrug 5-FC or camptothecin-11 (CPT-11),
respectively (Kim et al., 2010). Of translational significance,
HB1.F3.CD NSCs plus 5-FC is currently in first-in-human
phase I clinical trials for recurrent brain tumors (Aboody et
al., 2011).
In the current study, CD and IFN-β genes were fused and
transduced into HB1.F3 cells for stable expression, to examine
the potential cytotoxic effect of the therapeutic products
5-FU (in the presence of 5-FC) and IFN-β on breast cancer
cells. Interferons (IFNs) are cytotoxic cytokines that are
released by lymphocytes of host cells responding to viral
infection and activate immune cells by up-regulating antigen
presentation (Yoshiji et al., 2005). IFNs aremainly divided two
groups: type І IFN and type II IFN (Sottini et al., 2009).
IFN-alpha (IFN-α), IFN-beta (IFN-β), and IFN-omega (IFN-ω)
belong to type І IFN class, and IFN-gamma (IFN-γ) belongs to
type II IFN (Uze and Monneron, 2007). In humans, IFN-α, IFN-ω
and especially IFN-β expression strongly inhibit tumor cell
growth and induce apoptosis by Jak-Stat1 intracellular
signaling pathways, including immunomodulatory and
anti-angiogenic effects, in vitro and in vivo (Matsuzuka et
al., 2009). These functions of the type І IFN family are
mediated by a common cell surface receptor known as type І
IFN receptor (Pestka et al., 2004; Rosewicz et al., 2004).
Despite the strong anti-proliferative effect of IFN-β on cancer
cell growth, the underlying mechanism has not been success-
fully elucidated in vivo because of its exceptionally short
half-life (Oie et al., 2006). We therefore investigated whether
CD.IFN-β expressing hNSCs could migrate to breast cancer
cells and exert a more potent therapeutic effect in the
presence of 5-FC in a co-culture system in vitro and a mouse
mammary fat pad xenograft model in vivo.
2. Materials and methods
2.1. Cell culture
Two human breast cancer cell lines, MDA-MB-231 and MCF-7,
were purchased from Korean cell line bank (KCLB, Seoul,
Korea). Also, MDA-MB-231/luc cells expressing firefly
38 B.-R. Yi et al.luciferase as a bioluminescent reporter gene were purchased
from KOMA Biotechnology (Seoul, Korea). Three types of NSCs
(HB1.F3, HB1.F3.CD, and HB1.F3.CD.IFN-β) generated by us
and primary bovine fibroblasts (bovine FBs) were used in these
studies (Aboody et al., 2006). Briefly, HB1.F3.CD line was
constructed using the retroviral pBabePuro to include the CD
cDNA and the cells were selected with 3 μg/ml puromycin.
The clonal HB1.F3.CD.IFN-β line was derived from HB1.F3.CD
cells. An expression plasmid was constructed using the
retroviral pLHCX backbone to include the human IFN-β
cDNA. The viral supernatant and HB1.F3.CD cells were
incubated in the presence of polybrene (8 μg/ml). The
transduced cells were then selected with 5 μg/ml hygromycin
(Lee et al., 2009). All cells were cultured in Dulbecco's
Modified Eagle's Medium (DMEM; Hyclone Laboratories, Logan,
UT, USA) plus 10% heat-inactivated fetal bovine serum (FBS;
Hyclone Laboratories), 100 U/ml penicillin G and 100 μg/ml
streptomycin (Cellgro Mediatech, Manassas, VA, USA), 10 mM
HEPES (Invitrogen Life Technologies, Carlsbad, CA, USA) and
anti-mycoplasmal agents (Invivogene, San Diego, CA, USA) at
37 °C in 5% CO2 and 95% air in a humidified cell incubator.
2.2. RNA extraction and reverse transcription
polymerase chain reaction (RT-PCR)
Total RNA was extracted from hNSCs and breast cancer cells
using TriZol reagent (Invitrogen Life Technologies). Following
the manufacturer's protocols, 1 μg of total RNA quantified via
spectrophotometer (Optizen, Mecasys, Deajeon, Korea) was
reverse transcribed into complementary DNA (cDNA) using
murine leukemia virus reverse transcriptase (MMLV-RT;
iNtRON Biotechnology, Sungnam, Korea), 200 pM nonamer
random primer (TaKaRa Bio, Shiga, Japan), 10 pM dNTP
(Bioneer, Deajeon, Korea), RNase inhibitor (iNtRON Biotech-
nology), and 5× RT buffer. To confirm the expression of
bacterial CD and human IFN-β genes in hNSCs, cDNA (1 μl)
from total RNA of hNSCs was amplified using the respective
primers by PCR. PCR was also conducted using the cDNA of
cancer cells to amplify the chemoattractant ligands and
receptors, including SCF, c-kit, VEGF, and VEGF receptor 2Table 1 Sequences of the primers employed and the expected s
mRNA Oligo-sequenc
CD Sense GCGCGAGTCA
Antisense GTTTGTAATC
IFN-β Sense AAAGAAGCAG
Antisense TTTCTCCAGT
SCF Sense ACTTGGATTC
Antisense CTTTCTCAGG
VEGF Sense AAGCCATCCT
Antisense GCTCCTTCCT
VEGFR2 Sense ACGCTGACAT
Antisense GCCAAGCTTG
c-kit Sense GCCCACAATA
Antisense AGCATCTTTA
hIFNAR2 Sense ATTCATATGA
Antisense GACTTTGGGG
GAPDH Sense ATGTTCGTCA
Antisense TGGCAGGTTT(VEGFR2) with sense and antisense primers based on the
published sequence of the genes, respectively. Human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene
was used as a positive control and PCR mixture without a
cDNA template negative control. The sense and antisense
oligo-sequences and the expected size of RT-PCR products are
described in Table 1. The PCR mixture was composed of each
10 pmol sense and antisense primer (Bioneer), 2 unit Taq
polymerase (iNtRON Biotechnology), 10× PCR buffer (iNtRON
Biotechnology), 5 pmol dNTPmixtures (Bioneer) and template
(cDNA). The PCR reactions were performed for 30 cycles in
denaturation for 30 s at 95 °C, annealing for 30 s at 58 °C,
and extension for 30 s at 72 °C. The reaction products (8 μl)
were analyzed on a 1.5% agarose gel pre-stainedwith ethidium
bromide (EtBr; Sigma-Aldrich, St. Louis, MO, USA). The gels
were scanned by a Gel Doc 2000 apparatus (Bio-Rad
Laboratories, Hercules, CA, USA) and compared to a 100 bp
ladder of DNA (iNtRON Biotechnology).
2.3. In vitro migration assay
To confirm the migration ability of our genetically modified
hNSCs toward breast cancer cells, a modified Transwell
migration assay was performed. On the first day, breast cancer
cells (MCF-7 or MDA-MB-231; 1 × 105 cells/well) and bovine FB
cells as a control (1 × 105 cells/well) were seeded in 24-well
plates. After incubation for 6 h at 37 °C, the medium was
changed to serum free medium for 24 h. Before incubation,
bottoms of transwell (8 μm; BD Biosciences, Franklin Lakes,
NJ, USA) pre-coatedwith fibronectin (250 μg/ml; Sigma-Aldrich
Corp., St. Louis, MO, USA) were inserted in 24-well plates. On
the second day, hNSCs (1 × 105 cells/well) were labeled with
CM-DiI (Invitrogen Life Technologies) and plated in the upper
transwell chamber. CM-DiI staining was performed for a general
protocol. Briefly, hNSCs were trypsinized in a culture dish and
treated with CM-DiI solution (2 μM working solution) for 5 min
at 37 °C and then for an additional 15 min at 4 °C. After
labeling, cells were washed with phosphate buffered saline
(PBS) and resuspended in fresh medium. Pre-stained hNSCs
were seeded in upper chamber of transwell and incubated inizes of the PCR products.
e (5′- N 3′) Expected size (bp)
CCGCCAGCCACACCACGGC 559
GATGGCTTCTGGCTGC
CAATTTTCAG 296
TTTTCTTCCA
TCACTTGCATTT 505
ACTTAATGTTGAAG
GTGTGCCCCTGATG 377
CCTGCCCGGCTCAC
GTACGGTCTAT 438
TACCATGTGAG
GATTGGTATTT 570
CAGCGACAGTC
TTCGCCTGATTAC 758
AGGCTATTTCTTAA
TGGGTGTGAACCA 351
TTCTAGACGGCAG
39Stem cell mediated therapy for breast cancer37 °C. On the third day, breast cancer and bovine FB cells were
stained with 4′,6-diamidino-2-phenylindole solution (DAPI,
200 ng/ml; Invitrogen Life Technologies) and incubated in
each 24-well for 10 min at 37 °C in the dark. Each well was
washed two times with 1× PBS and the cells stained with CM-DiI
and DAPI were detected by fluorescent microscopy using an
IX71 inverted microscope and the number of red color hNSC
on the bottom of transwell was counted (Olympus, Tokyo,
Japan).
2.4. Cell viability assay
The cytotoxic effects of 5-FC, 5-FU, and three types of hNSCs
(HB1.F3, HB1.F3.CD, HB1.F3.CD.IFN-β) on breast cancer cells
were determined in the first two experiments. The first
experiment was done as follows: on day 1, MCF-7 and
MDA-MB-231 cells (4000 cells/well) were seeded in 96-well
plates (Thermo Fisher Scientific, Roskilde, Denmark). On day
2, three types of hNSCs (8000 cells/well) were added to the
breast cancer cells. On day 3, saline with a range of 5-FC
(Sigma-Aldrich Corp.) or 5-FU (Sigma-Aldrich Corp.) concen-
trations (100, 200, 300, 400, and 500 μg/ml) was added for
4 days. On day 7, the MTT (3-(4-,5-dimethylthiazol-2-yl)-2,
5-dyphenyl tetrazolium bromide) assay was performed to
measure cell viability. Ten microliters of MTT (Sigma-Aldrich
Corp.) stock solution (5 mg/ml in PBS) was added to each well
of a 96-well plate and incubated for 4 h at 37 °C. Precipitated
formazan crystals were dissolved in dimethyl sulfoxide (DMSO;
Junsei Chemical, Tokyo, Japan). Absorbance of each well was
measured at 540 nm using a VERSA man ELISA plate reader
(Molecular Devices, Sunnyvale, CA, USA). The second exper-
iment was performed in exactly the samemanner, but, on day
2, increasing numbers of hNSCs (8,000, 16,000, and 24,000
cells/well) were added to breast cancer cells in 96-well plates
and on day 3, 5-FC (500 μg/ml) was added. MTT assay was
performed as previously described. Each experiment was
carried out in duplicate with six individual samples (n = 6).
2.5. 5-FU treatment
MDA-MB-231 cells were seeded in 6-well plate for one day.
Next day, 5-FU diluted with PBS (0, 0.5, 1.0, and 5.0 μg/ml)
was treated in each well plate. Total RNA of 5-FU treated
breast cancer cells was extracted at 0, 3, 6, and 24 h and
RT-PCR was performed to detect human interferon alpha/
beta receptor 2 (hIFNAR2).
2.6. Breast cancer xenograft models
Thirty-six 6 week old female BALB/c nude mice were
purchased from Central Laboratory Animal (SLC, Shizuoka,
Japan) and the experiment progressed according to the
protocols approved by the Animal Care Committee of
Chungbuk National University. Briefly, mice were acclima-
tized in controlled room for at least 1 week prior to the
experiments (at 24–24 °C and 40–60% relative humidity
under a 12 h light/dark cycle and frequent ventilation).
Since acclimation of animals, breast cancer cells expressing
luciferase, MDA-MB-231/luc (2 × 106 cells/mouse), were
injected into the left mammary fat pad of the mice. Tumor
size of these orthotopic xenograft models was measured byusing a caliper every week and tumor volume was calculated
by 0.5236 × length × width × high.
2.7. In vivo therapeutic efficacy of HB1.F3.CD and
HB1.F3.CD.IFN-β hNSCs
To identify therapeutic efficacy in mammary fat pad xenograft
mouse model, mice were divided into four experimental
groups; Group 1 was a negative control group treated with
0.85% saline instead of the hNSCs plus 5-FC. Group 2 was
treatedwith HB1.F3 hNSCs plus 5-FC (500 mg/kg/day). Group 3
was treated with HB1.F3.CD hNSCs plus 5-FC (500 mg/kg/day).
Group 4 was treated with HB1.F3.CD.IFN-β hNSCs plus 5-FC
(500 mg/kg/day). These experiments progressed for 4 weeks
post-NSC injection. When tumor volume reached 250 mm3, we
injected 8 × 106 NSCs next to the breast tumor mass. These
hNSCs were pre-labeled with a CM-DiI cell tracker prior to
injection, for ease of detection post-sacrifice. hNSCs were
injected to the adjacent breast cancer mass for a total of three
times during the experimental period. Two days after the
injection of hNSCs, the Group 1 received intraperitoneal (i.p.)
injections of normal saline (100 μl), while Groups 2, 3, and 4
received i.p. injections of 5-FC (500 mg/kg/day in 100 μl
saline) everyday for 5 days. Forty-eight hours after the last
5-FC treatment, mice were sacrificed and tumor or skin tissues
were harvested for analysis.
2.8. In vivo bioluminescent imaging
Bioluminescent imaging was performed with a charge-coupled
(CCD) camera having photon emitting properties via a
particular enzyme (luciferase)-substrate (D-luciferin) reaction
(Day et al., 2004). For in vivo imaging, breast cancer
xenografts implanted with MDA-MB-231/Luc were given the
luciferase substrate, D-luciferin (Promega, Madison, WI, USA)
through an i.p. injection (150 μg/kg) and anesthetized with
1–3% isoflurane. Ten minutes later, bioluminescent tumor
cells were detected by the CCD camera mounted in a light-
tight box (IVIS™ Xenogen; Caliper Life Sciences, Hopkinton,
MA, USA) and tumor regions quantified as total photon
counter and photons/s using Living Image controlled
imaging analysis software (Caliper Life Sciences).
2.9. Histopathology
For histopathological analysis, breast cancer xenografts and
skin tissues excised from themice at necropsy were fixed at 10%
normal formalin solution (Sigma-Aldrich Corp.). These fixed
samples were cut into 4–6 mm thick sections, embedded in
paraffin, and microtome sectioned at a thickness of 5 μm.
Prepared slides were stained using hematoxylin (Sigma-Aldrich
Corp.) and eosin (Sigma-Aldrich Corp.) staining methods. In
stained slides, skin and surrounding tissue basis structure and
cancer cells were observed by light microscopy using a model
BX51 microscope (Olympus).
2.10. DAPI staining
To observe the distribution of hNSC's (Di-I fluorescent red) in
the breast cancer mass, 4′,6-diamidino-2-phenylindole (DAPI—
40 B.-R. Yi et al.nuclei fluorescent blue) staining was performed in prepared
tumor section slides. After rehydration, slides were fixed with
10% normal formalin (Sigma-Aldrich Corp.) solution for 10 min,
washed using PBS two times, and treated with DAPI for 10 min
at 37 °C. Slides were mounted with coverslips and observed by
fluorescent microscopy using an IX71 inverted microscope
(Olympus).2.11. Statistical analysis
Data from each experiment are presented as the mean ±
standard deviation (S.D.) or the mean ± standard error of
the mean (SEM). To evaluate the significance of each in vitro
and in vivo group, statistical analysis was performed by
one-way ANOVA Tukey's test using Prism Graph Pad (v5.0;
GraphPad Software, San Diego, CA, USA). P b 0.05 was
considered statistically significant.3. Results
3.1. Identification of CD and human IFN-β genes
The expression of E. coli CD and human IFN-β genes was
measured by RT-PCR. CD cDNA was detected at 296 bp in
both HB1.F3.CD and HB1.F3.CD.IFN-β cells and human IFN-β
cDNA at 559 bp in only HB1.F3.CD.IFN-β cells (Fig. 1), thus
demonstrating the effective and stable transduction of these
genes into HB1.F3 hNSCs. The GAPDH gene was detected at
351 bp in HB1.F3, HB1.F3.CD, and HB1.CD.IFN-β cells
(Fig. 1).Figure 1 RT-PCR of E. coli CD and human IFN-β gene
expression in engineered hNSCs. After total RNA extraction
from HB1.F3.CD and HB1.F3.CD.IFN-β cells, cDNAs were
synthesized by reverse transcription (RT) reaction. The cDNA
was amplified by PCR and PCR product was confirmed via 1.5%
agarose gel electrophoresis. E. coli CD and human IFN-β cDNA
were detected at 559 bp and 296 bp, respectively. GAPDH was
used to a positive control and detected at 351 bp. PCR mixture
without a cDNA template is a negative control. Mwt; 100 bp
molecular weight marker, a; Negative control (without cDNA
template), b; HB1.F3, c; HB1.F3.CD, d; HB1.F3.CD.IFN-β.3.2. In vitro migration of hNSCs toward breast
cancer cells
A modified Transwell migration assay was performed to
measure the capacity of the hNSCs to migrate toward breast
cancer cells. hNSCs (DiI labeled) demonstrated significant
migration toMCF-7 andMDA-MB-231 cells, but not to bovine FB
cells (Fig. 2A). The number of migrated hNSCs to MCF-7 or
MDA-MB-231 breast cancer or bovine FB cells on the bottom of
transwell was counted using fluorescent microscopy. Results
confirmed significantmigration of hNSCs to breast cancer cells
vs. control non-tumorigenic fibroblasts. Each experiment was
performed independently and presented as mean ± S.D. for
verification of migrated hNSC number compared to migrated
bovine FB (Fig. 2B). It was noted that there was no significant
difference in the migration between the HB1.F3, HB1.F3.CD
and HB1.F3.CD.IFN-β hNSCs. These results suggest that
transgene introduction into stem cells does not affect their
migration to breast cancer cells.
In addition, a potential interaction of chemoattractant
ligands and their receptors would be a major reason for
tumor-tropic effect of engineered stem cells in vitro and in
vivo. Using a general protocol of RT-PCR, we confirmed the
expressions of chemoattractant factors, i.e., SCF, VEGF,
VEGFR2, and c-kit, in breast cancer and HB1.F3 cells. The
chemoattractant ligands, SCF and VEGF, were strongly
expressed in MDA-MB-231 and MCF-7 breast cancer cells,
while their receptors including c-kit and VEGFR2 were
detected in HB1.F3 cells as shown in Fig. 2C.
3.3. Therapeutic efficacy of HB1.F3.CD and
HB1.F3.CD.IFN-β hNSCs with 5-FC in vitro
To determine the cytotoxic effects of 5-FC and 5-FU on breast
cancer cells, the MTT assay was performed. Although treat-
ment with 5-FC did not induce any effect of cancer cell growth,
5-FU markedly decreased cell proliferation by approximately
80% (Fig. 3A). Next, using co-culture system with MDA-MB-231
or MCF-7 cells, we measured the cytotoxic activity of hNSCs on
breast cancer cells at different concentrations of 5-FC (100 to
500 μg/ml). Cell proliferation of breast cancer cells was
significantly inhibited by HB1.F3.CD and HB1.F3.CD.IFN-β
cells in the presence of 5-FC. When the number of hNSCs was
fixed, the inhibition effect was increased with increased
concentrations of 5-FC. When we compared the cytotoxic
effects between HB1.F3.CD.IFN-β and HB1.F3.CD hNSCs
presence of 5-FC on breast cancer cells, significantly stronger
inhibition was observed by HB1.F3.CD.IFN-β cells compared to
HB1.F3.CD cells (P b 0.05 for MDA-MB-231 cells). These data
indicate that IFN-β has an additional cytotoxic effect to 5-FU as
seen in Fig. 3B. Specifically, the cell viability of MDA-MB-231
cells was decreased by 60%when treatedwithHB1.F3.CD.IFN-β
cells as compared to a decrease in cell viability by 40% when
treated with the HB1.F3.CD cells under the same conditions
(P b .05).
3.4. Upregulation of hIFNAR2 expression in
MDA-MB-231 cells
To confirm the change of hIFNAR2 expression, serial diluted
5-FU (0, 0.5, 1.0, and 5.0 μg/ml) was treated in 6-well plate
Figure 2 In vitro migration of hNSCs toward breast cancer cells. MDA-MB-231 and MCF-7 breast cancer cells or bovine FB cells (as a
control) were seeded with 10% FBS culture media in 24-well plates (1 × 105 cells/well). Next day, CM-Dil pre-labeled hNSCs: HB1.F3,
HB1.F3.CD, and HB1.F3.IFN-β (1 × 105 cells/well) were added to each upper Transwell chamber for 24 h. The cancer cells and bovine FB
in the 24-well plate were stained with DAPI. A, Themigration of hNSCs to MDA-MB-231, MCF-7 and bovine FB cells was detected under the
microscope. Blue: DAPI stained nuclei of breast cancer or bovine FB cells in the each well, Red: CM-DiI hNSCs (HB1.F3, HB1.F3.CD, and
HB1.F3.CD.IFN-β). B, The number of migrated hNSCs to breast cancer or bovine FB cells was counted using fluorescent microscopy. Each
experiment was performed independently and presented as mean ± S.D. *P b 0.05 vs. a bovine FB. C, Chemoattractant molecules, i.e.,
SCF, VEGF, VEGFR2, and c-kit, were identified in breast cancer cells and stem cells (HB1.F3) by RT-PCR. Scale bar: 200 μm, Mwt: 100 bp
molecular weight marker a; negative control without cDNA template, b; MDA-MB-231, c; MCF-7.
41Stem cell mediated therapy for breast cancerseeded in MDA-MB-231 cells and total RNA was extracted from
MDA-MB-231 cells after 0, 3, 6, and 24 h. In normal state (not
treated 5-FU), IFNAR2 gene was weakly or rarely expressed in
MDA-MB-231 cells according to treatment time and dose.
Enhanced mRNA expression levels for hIFNAR2 were observed
in breast cancer cells treated with even small amount of 5-FU
(0.5, 1.0, and 5.0 μg/ml) as shown in Fig. 4A. Also, expression
of this gene was increased in a time-dependent manner. When
treated with 1.0 μg/ml of 5-FU, the expression of hIFNAR2
began to increase from 6 h until 24 h. Finally, 5-FU induced an
enhanced expression of hIFNAR2 gene up to about 2.3-fold in
MDA-MB-231 cells (Fig. 4B).3.5. Tumor mass measurement in xenograft models
Four weeks after the injection of MDA-MB-231/luc cells to
female BALB/c nude mice, a breast tumor was formed in left
mammary fat pad of each mouse. Overall experimentalschedule is presented in Fig. 5A. From the sixth week during
the experiment period, the growth of each breast tumor mass
was inhibited by HB1.F3.CD or HB1.F3.CD.IFN-β cells with
treatment of 5-FC (500 mg/kg/day). The tumor mass was
inhibited by approximately 50% in both groups compared to
control group (Figs. 5B and C). This result clearly demonstrates
the therapeutic efficacy of HB1.F3.CD and HB1.F3.CD.IFN-β
cells in vivo. But, HB1.F3.CD.IFN-β cells did not seem to have
the additional effect in decreasing the tumor volume
compared to HB1.F3.CD cells, as demonstrated in vitro.
3.6. Bioluminescence imaging of breast cancer
growth and survival rate in xenograft models
We also observed tumor state of xenografts more vividly using
the bioluminescence imaging assay. Because MDA-MB-231/luc
cells implanted into a mouse emit the photons in the presence
of D-luciferin, the value of emitted photons measured by CCD
Figure 3 Therapeutic efficacy of HB1.F3.CD and HB1.F3.CD.IFN-β with 5-FC in vitro. After MDA-MB-231 or MCF-7 (4 × 103 cells/well)
were seeded in 96-well plates for 24 h, stem cells were co-cultured in the presence of 5-FC for another 24 h. After 4 days, the cell
viability was measured by MTT assay. A, The cytotoxic effect on breast cancer cells of various concentrations of 5-FC or 5-FU (100, 200,
300, 400, and 500 μg/ml) was measured. B, The breast cancer cells were cultured with HB1.F3, HB1.F3.CD, or HB1.F3.CD.IFN-β hNSCs
(8 × 103 cells/well) and treated with increasing concentrations of 5-FC (100, 200, 300, 400, and 500 μg/ml). Each experimentwas carried
out independently and presented as mean ± S.D. *P b 0.05 vs. HB1.F3, **P b 0.05 vs. HB1.F3.CD.
Figure 4 Potentiation of human interferon alpha/beta receptor
2 (hIFNAR2) activation by 5-FU. Various 5-FU diluted with PBS (0,
0.5, 1.0, and 5.0 μg/ml) were treated in 96-well plate seeded
MDA-MB-231. Total RANs of MDA-MB-231 cells were extracted in
each time (0, 3, 6, 9, and 24 h). cDNA synthesized fromeach sample
was performed the PCR reaction using by IFNAR2 specific primer. A,
hIFNAR2 gene was confirmed by 1.5% agarose gel electrophoresis
pre-stained with EtBr. B, Quantification of PCR product was shown
in a graft by Quantity One analysis system. Date are represented as
mean ± SD. *, P b 0.05 vs. 0 h as a control.
42 B.-R. Yi et al.camera in bioluminescent imaging precisely represented the
tumor size in living animals. Results show that the photon
quantity was significantly decreased in mice injected with
HB1.F3.CD and HB1.F3.CD.IFN-β cells, while it continuously
increased in the mice injected with saline or HB1.F3 cells
only (Figs. 6A and B). In addition, the treatment with
HB1.F3.CD.IFN-β cells resulted in a significant decrease in the
tumor volume as compared to HB1.F3.CD cells, indicating the
additional antitumor activity of IFN-β in the presence of 5-FU in
an in vivo mouse xenograft model.
When we measured the survival rate, the mice treated
with HB1.F3.CD.IFN-β cells survived significantly longer than
any other groups (P b 0.05). Whereas the mice treated with
HB1.F3.CD.IFN-β cells plus 5-FC showed a survival rate of
80% at 14 weeks, the mice with HB1.F3.CD cells showed 30%
survival at 13 weeks, and all died at 14 weeks. All the mice
of the negative control and HB1.F3 treated groups died by
week 8 as shown in Fig. 6C. These data further confirm the
stronger anti-cancer effect in vivo of HB1.F3.CD.IFN-β cells
as compared to the HB1.F3.CD cells in the presence of 5-FC.
These data support the more potent effect of CD/5-FC plus
IFN-β than CD/5-FC alone in the killing effect against ductal
breast cancer cells.3.7. Histological and fluorescent analysis of breast
cancer mass and circumferential tissues
To assess alterations in the histopathological aspects of the
tumor mass and its surrounding tissues, we previously
Figure 5 Experimental schedule of in vivo test and measurement of tumor mass volume. A, Xenograft models were manufactured by
implanting MDA-MB-231/luc cells to female BALB/c nude mice. Four week after cancer cell injection, pre-stained hNSCs (8 × 106 cells/
mouse) were injected nearby tumor mass. Two days later, 5-fluorocytosine (5-FC, 500 mg/kg/day) was treated every day. And the animals
were sacrificed 2 days after last injection. B, Formed tumor sizes were measured for 8 weeks and the tumor volumes were calculated by
0.5236 × length × width × high. C, Tumor volumes measured at the final week were shown in the graph. Data points are represented as
mean ± SEM. *, P b 0.05 vs. NC. NC, negative control.
43Stem cell mediated therapy for breast cancerobserved the normal tissue structure of the mammary fat pad
in a mouse (i.e., epidermis, dermis, fat, and muscle layer) as
shown in Fig. 7A. In control and HB1.F3 treated groups, the
normal structure of mammary fat pad was ravaged by the
invasive growth of breast cancer cells. However, we con-
firmed that the growth of implanted tumor cells was inhibited
inside the tumor mass and the tissue structure was maintained
relatively intact in the mice implanted with HB1.F3.CD and
HB1.F3.CD.IFN-β cells plus 5-FC (Fig. 7B). Additionally, in the
mice with HB1.F3.CD.IFN-β cells, the nuclear size of the
tumor cells was decreased and macrophages and master cells
related with immune response emerged at the dermis and fat
layers compared to control and the mice injected with HB1.F3
only. To explain these phenomena (i.e., immune response in
the marginal skin, tumor growth inhibition, and the preserva-
tion of tissue structure by hNSCs), we performed a fluorescent
analysis using CM-DiI pre-labeled hNSCs injected adjacent to
the ductal breast tumor mass. We found the positioning of the
red fluorescent hNSCs inside the tumor mass as demonstrated
in Fig. 8, indicating that these hNSCs effectively distributedthrough the tumor mass and exerted their anti-tumor activity
by the products of delivered genes. It is also noteworthy that
more HB1.F3.CD.IFN-β cells were detected at tumor sites than
HB1.F3.CD cells following treatment with 5-FC, despite the
same number hNSCs injected.4. Discussion
Conventional cancer therapies (radiotherapy, hormone therapy,
and chemotherapy) for breast cancer have many undesirable
side effects (McArthur et al., 2011; Piccart, 2003). Gene therapy
delivered by a packaging line or viruses with activated ‘suicide’
genes appears to selectively treat cancers, however the
packaging line stayed at or near injection sites and virus only
reached neighboring tumor cells. The inability of virus to deliver
therapeutic genes to invading and distant tumor sites greatly
limits its effectiveness. The enzyme/prodrug distribution and
efficacy of gene delivery mediators, i.e., adenovirus and
lentivirus, is also questionable (Pastorakova et al., 2006). A
Figure 6 Bioluminescent imaging by luciferase in breast cancer xenografts and survival rate. A, D-luciferin, a substrate of
luciferase (150 μg/kg) was injected via intraperitoneal injection in mice. At 10 min after injection, the converted D-luciferin was
measured in the value of emitted photons. During the experimental period, alteration of tumor size in each group was shown by
bioluminescent imaging by CCD camera. B, Photon values of tumor mass were displayed in the graph. C, The survival rate for the
breast cancer xenografts was measured during the experimental period, and expressed as a percent of the initial number of mice in
each group. The mice injected with HB1.F3.CD.IFN-β cells showed 80% survival rate at the end of experiment. Data are represented
as mean ± SEM. *, P b 0.05 vs. a negative control, **P b 0.05 vs. HB1.F3.CD. NC: negative control.
44 B.-R. Yi et al.tumor specific delivery system is critical for enhancing the
selective effectiveness of well-known prodrugs for de novo
various tumors. NSCs overcome these limitations of current
gene therapy systems by targeting invasive and distant tumor
foci and expressing the ‘suicide’ genes locally. To minimize
systemic toxicities, NDEPT has received much attention for
cancer-targeted therapy (Kim et al., 2010; Nawa et al., 2008).
These gene therapies use viral vectors as vehicles to transport
prodrug activating or ‘suicide’ genes, which convert a non-toxic
prodrug to a toxic agent (Anderson, 2000). This leads to a
bystander effect, where not only the suicide gene transduced
vehicle cells, but also the untransfected neighboring target cells
are eradicated (Kang et al., 2012d). Typical enzyme/prodrug
therapy systems are CD/5-FC, CE/CPT-11, and thymidine kinase
(TK)/ganciclovir (GCV) (Kang et al., 2012c; Shah, 2012). In
previous studies, the antitumor effects of CD/5-FC and CE/
CPT-11 were demonstrated in animal models of disseminated
neuroblastoma (Kim et al., 2010), intracranial medulloblastoma
(Kim et al., 2006a), and glioma (Kang et al., 2012b; Longley et
al., 2003).
Recently, inherently tumor-tropic stem cells have received
a great deal of attention for their clinical potential to treat
diverse human cancers. For example, hNSCs are reported tobe very effective in delivering various therapeutic agents in
preclinical models of malignant brain tumors including
medulloblastoma and glioma (Kim et al., 2006a, 2006b; Thu
et al., 2009) and other invasive tumors (Kim et al., 2010;
Longley et al., 2003). Mesenchymal stem cells (MSCs) have
also been employed as a systemic delivery vehicle for
therapeutic genes to breast cancer because they can home
to tumor sites and evade host immune responses (Conrad et
al., 2011; El Haddad et al., 2011; Niess et al., 2011).
In the current studies, we employed HB1.F3 cells, an
immortalized human clonal NSC line, as a therapeutic gene
delivery vehicle to target breast cancer and to disseminate gene
products throughout tumor sites (Kim et al., 2002). HB1.F3, one
of NSCs, is homogeneous since they are generated from a single
clone and can be stably expanded to large numbers in vitro. It is
of interest to note that the HB1.F3 canmigrate to subcutaneous
xenografts of various non-neural solid tumors types, including
prostate, breast, and melanoma, indicating a broader range
of potential clinical application (Aboody et al., 2006). To
investigate therapeutic applications to breast cancer, we
engineered HB1.F3 cells to stably express the therapeutic
genes CD (HB1.F3.CD) and human IFN-β (HB1.F3.CD.IFN-β). We
hypothesized that this NDEPT approach has the potential to
Figure 7 Histological analysis of breast tumor mass and skin extracted from mice. Breast cancer tissues excised from the mice at
necropsy were fixed at 10% normal formalin solution. These fixed samples were cut into 4–6 mm thick sections, embedded in
paraffin, and microtome sectioned (5 μm). Tissue sections were stained with hematoxylin and eosin (H&E). A, Tumor structure of
mammary pad of the mice in each group. E; epidermis, D; dermis, F; fat layer, M; muscle layer, large arrow; immune responded cells.
Magnifications ×40 and ×100. B, High power views of H&E stained tumor sections. Magnification ×400.
45Stem cell mediated therapy for breast cancerimprove clinical outcome, while minimizing toxic side effects.
We first verified the tumor-tropism of our genetically modified
NSC lines in a modified Transwell assay, which demonstrated
significant directedmigration to MCF-7 and MDA-MB-231 human
breast tumor lines, but not to non-tumorigenic bovine FB
cells. Although the specific molecular mechanism of NSC
tumor-tropism has not been clearly elucidated, numerous
chemokines are likely involved. Zhao et al. have recently
demonstrated the role of IL-6 in NSC migration toward breast
cancer metastases (Zhao et al., 2012). In this study, we
confirmed that MCF-7 and MDA-MB-231 breast cancer cells
strongly expressed chemoattractant ligands including SCF and
VEGF, while the HB1.F3 cells showed the corresponding
receptors, c-kit and VEGFR2, likely contributing to their tropic
and migratory capacity. In particular, MDA-MB-231 cells
expressed high levels of VEGF, which is a chemoattractant
factor and a primary stimulant of angiogenesis (Di Domenico et
al., 2010). Further study is required to verify the role of these
factors in the mechanism of tumor cell recognition and/or
tumor tropism by stem cells.
Next, in the cell viability study, HB1.F3.CD.IFN-β and
HB1.F3.CD cells showed a high rate of cytotoxic activity on
breast cancer cells, particularly MDA-MB-231 cells, in the
presence of the prodrug 5-FC. Greater growth inhibition was
observed for HB1.F3.CD.IFN-β cells compared to HB1.F3.CD,
indicating that an additional cytotoxic effect of IFN-βresulting from the immunotherapy along with 5-FU generat-
ed from CD/5-FC may provide a ‘double-punch’ strategy of
chemotherapy. 5-FU has been reported to induce the
expression of IFN α/β receptor (IFNAR), which plays a
role in increasing the cytokine activity of IFN-β (Oie et al.,
2006; Wagner et al., 2004). In our study, enhanced mRNA
expression of hIFNAR2 was observed at the concentrations of
5-FU (0.5, 1.0, and 5.0 μg/ml). Thus, the susceptibility of
breast cancer cells to IFN-β appears to be increased by the
5-FU generated from CD/5-FC in this system. It has been
previously reported that other immune responses or apopto-
tic factors may be involved in NDEPT-induced antitumor
effects (Qiao et al., 2000). Thus, further studies are
warranted to clarify the underlying mechanism of IFN-β
with CD/5-FC system.
Finally, we confirmed the therapeutic efficacy of our
NSC-mediated approach in vivo in a mammary fat pad ductal
breast cancer xenograft model. NSCs expressing CD +/−
IFN-β significantly inhibited growth of tumor masses.
Specifically, in both bioluminescent imaging and long-term
survival analysis, the HB1.F3.CD.IFN-β group showed a
stronger inhibitory effect on tumor growth than the
HB1.F3.CD group, consistent with the cell viability assay in
vitro. The effect of increased lifespan can be induced by
transduced human IFN-β in HB.F3.CD.IFN-β because of the
adaptive immune system in a xenograft mouse model.
Figure 8 Fluorescent analysis of breast tumor mass. hNSCs were pre-labeled with CM-DiI cell tracker prior to injection. After
preparing tumor section slides, DAPI counterstaining was performed. Stained slides were mounted with coverslips and observed by a
microscopy. Magnification ×100, Blue: DAPI stained nuclei of breast cancer cells (dense blue) and hNSCs, Red: CM-DiI labeled hNSCs,
B: boundary.
46 B.-R. Yi et al.Histological analysis of tumor sections of mice that received
the therapeutic NSCs displayed preservation of normal
structures, i.e., epidermis, dermis, fat, and muscle layer.
On the other hand, the tissue structures of control mice
injected with non-modified HB1.F3 cells were damaged by
the progressive growth of breast cancer cells. Therefore,
we suggested that modified NSCs have a strong therapeutic
potential for prolongation of life-span.
Insummary,weconfirmthatHB1.F3.CDandHB1.F3.CD.IFN-β
cells selectively migrated toward breast cancer cells. This is
likely due to various chemokines expressed by the tumor cells
and their cognate receptors expressed on the stem cells, such
as SCF/c-kit and VEGF/VEGFR2, respectively. The viability of
breast cancer cells was significantly reduced by co-culture
with HB1.F3.CD and HB1.F3.CD.IFN-β in the presence of the
prodrug 5-FC. More effective inhibition was observed by
HB1.F3.CD.IFN-β compared to HB1.F3.CD. In vivo mouse
mammary fat pad xenograft efficacy studies revealed that
HB1.F3.CD.IFN-β cells exerted more potent anticancer effect
by simultaneously expressing fusion gene products of CD and
IFN-β. Taken together, these results suggest that our
engineered NSCs may provide a novel ductal breast cancer
treatment approach using a double-punch CD/5-FC enzyme/
prodrug and IFN-β immunotherapy strategy.Disclosure of Conflict of interest
KSA and SUK are co-founders and shareholders of TheraBiologics
Inc., a clinical stage biopharmaceutical company supporting
the development of NSC-mediated therapies for cancers.Acknowledgments
This work was supported by a National Research Foundation of Korea
(NRF) grant funded by theMinistry of Education, Science andTechnology
(MEST) of the Republic of Korea government (no. 2011-0015385).
References
Aboody, K.S., Bush, R.A., Garcia, E., Metz, M.Z., Najbauer, J.,
Justus, K.A., Phelps, D.A., Remack, J.S., Yoon, K.J., Gillespie,
S., Kim, S.U., Glackin, C.A., Potter, P.M., Danks, M.K., 2006.
Development of a tumor-selective approach to treat metastatic
cancer. PLoS One 1, e23.
Aboody, K.S., Najbauer, J., Danks, M.K., 2008. Stemandprogenitor cell-
mediated tumor selective gene therapy. Gene Ther. 15, 739–752.
Aboody, K., Capela, A., Niazi, N., Stern, J.H., Temple, S., 2011.
Translating stem cell studies to the clinic for CNS repair: current
47Stem cell mediated therapy for breast cancerstate of the art and the need for a Rosetta Stone. Neuron 70,
597–613.
Anderson, W.F., 2000. Gene therapy scores against cancer. Nat.
Med. 6, 862–863.
Bevers, T.B., Anderson, B.O., Bonaccio, E., Buys, S., Daly, M.B.,
Dempsey, P.J., Farrar, W.B., Fleming, I., Garber, J.E., Harris,
R.E., Heerdt, A.S., Helvie, M., Huff, J.G., Khakpour, N., Khan,
S.A., Krontiras, H., Lyman, G., Rafferty, E., Shaw, S., Smith,
M.L., Tsangaris, T.N., Williams, C., Yankeelov, T., 2009. NCCN
clinical practice guidelines in oncology: breast cancer screening
and diagnosis. J. Natl. Compr. Cancer Netw. 7, 1060–1096.
Conrad, C., Husemann, Y., Niess, H., von Luettichau, I., Huss, R.,
Bauer, C., Jauch, K.W., Klein, C.A., Bruns, C., Nelson, P.J.,
2011. Linking transgene expression of engineered mesenchymal
stem cells and angiopoietin-1-induced differentiation to target
cancer angiogenesis. Ann. Surg. 253, 566–571.
Danks, M.K., Yoon, K.J., Bush, R.A., Remack, J.S., Wierdl, M.,
Tsurkan, L., Kim, S.U., Garcia, E., Metz, M.Z., Najbauer, J.,
Potter, P.M., Aboody, K.S., 2007. Tumor-targeted enzyme/
prodrug therapy mediates long-term disease-free survival of
mice bearing disseminated neuroblastoma. Cancer Res. 67,
22–25.
Day, J.C., Tisi, L.C., Bailey, M.J., 2004. Evolution of beetle biolumines-
cence: the origin of beetle luciferin. Luminescence 19, 8–20.
Di Domenico, M., Ricciardi, C., Fusco, A., Pierantoni, G.M., 2010.
Anti-VEGF therapy in breast and lung mouse models of cancers.
J. Biomed. Biotechnol. 2011, 947928.
El Haddad, N., Heathcote, D., Moore, R., Yang, S., Azzi, J., Mfarrej,
B., Atkinson, M., Sayegh, M.H., Lee, J.S., Ashton-Rickardt, P.G.,
Abdi, R., 2011. Mesenchymal stem cells express serine protease
inhibitor to evade the host immune response. Blood 117,
1176–1183.
Fuchita, M., Ardiani, A., Zhao, L., Serve, K., Stoddard, B.L., Black,
M.E., 2009. Bacterial cytosine deaminase mutants created
by molecular engineering show improved 5-fluorocytosine-
mediated cell killing in vitro and in vivo. Cancer Res. 69,
4791–4799.
Hernandez-Alcoceba, R., Sangro, B., Prieto, J., 2006. Gene therapy
of liver cancer. World J. Gastroenterol. 12, 6085–6097.
Kang, N.H., Hwang, K.A., Kim, S.U., Kim, Y.B., Hyun, S.H., Jeung,
E.B., Choi, K.C., 2012a. Potential antitumor therapeutic strat-
egies of human amniotic membrane and amniotic fluid-derived
stem cells. Cancer Gene Ther. 19, 517–522.
Kang, N.H., Hwang, K.A., Yi, B.R., Lee, H.J., Jeung, E.B., Kim, S.U.,
Choi, K.C., 2012b. Human amniotic fluid-derived stem cells
expressing cytosine deaminase and thymidine kinase inhibits the
growth of breast cancer cells in cellular and xenograft mouse
models. Cancer Gene Ther. 19, 412–419.
Kang, N.H., Lee, W.K., Yi, B.R., Park, M.A., Lee, H.R., Park, S.K.,
Hwang, K.A., Park, H.K., Choi, K.C., 2012c. Modulation of lipid
metabolism by mixtures of protamine and chitooligosaccharide
through pancreatic lipase inhibitory activity in a rat model. Lab.
Anim. Res. 28, 31–38.
Kang, N.H., Yi, B.R., Lim, S.Y., Hwang, K.A., Baek, Y.S., Kang, K.S.,
Choi, K.C., 2012d. Human amniotic membrane-derived epithe-
lial stem cells display anticancer activity in BALB/c female nude
mice bearing disseminated breast cancer xenografts. Int.
J. Oncol. 40, 2022–2028.
Kim, S.U., Nakagawa, E., Hatori, K., Nagai, A., Lee, M.A., Bang,
J.H., 2002. Production of immortalized human neural crest stem
cells. Methods Mol. Biol. 198, 55–65.
Kim, S.K., Kim, S.U., Park, I.H., Bang, J.H., Aboody, K.S., Wang,
K.C., Cho, B.K., Kim, M., Menon, L.G., Black, P.M., Carroll, R.S.,
2006a. Human neural stem cells target experimental intracranial
medulloblastoma and deliver a therapeutic gene leading to
tumor regression. Clin. Cancer Res. 12, 5550–5556.
Kim, S.U., Park, I.H., Kim, T.H., Kim, K.S., Choi, H.B., Hong, S.H.,
Bang, J.H., Lee, M.A., Joo, I.S., Lee, C.S., Kim, Y.S., 2006b.Brain transplantation of human neural stem cells transduced
with tyrosine hydroxylase and GTP cyclohydrolase 1 provides
functional improvement in animal models of Parkinson disease.
Neuropathology 26, 129–140.
Kim, K.Y., Kim, S.U., Leung, P.C., Jeung, E.B., Choi, K.C., 2010.
Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian
cancer cells using genetically engineered stem cells: tumor-
tropic potential and inhibition of ovarian cancer cell growth.
Cancer Sci. 101, 955–962.
Lee, D.H., Ahn, Y., Kim, S.U., Wang, K.C., Cho, B.K., Phi, J.H.,
Park, I.H., Black, P.M., Carroll, R.S., Lee, J., Kim, S.K., 2009.
Targeting rat brainstem glioma using human neural stem cells
and human mesenchymal stem cells. Clin. Cancer Res. 15,
4925–4934.
Lim, L.Y., Vidnovic, N., Ellisen, L.W., Leong, C.O., 2009. Mutant p53
mediates survival of breast cancer cells. Br. J. Cancer 101,
1606–1612.
Longley, D.B., Harkin, D.P., Johnston, P.G., 2003. 5-fluorouracil:
mechanisms of action and clinical strategies. Nat. Rev. Cancer 3,
330–338.
Lv, H., Pan, G., Zheng, G., Wu, X., Ren, H., Liu, Y., Wen, J., 2010.
Expression and functions of the repressor element 1 (RE-1)-
silencing transcription factor (REST) in breast cancer. J. Cell.
Biochem. 110, 968–974.
Lynch, H.T., Silva, E., Snyder, C., Lynch, J.F., 2008. Hereditary
breast cancer: part I. Diagnosing hereditary breast cancer
syndromes. Breast J. 14, 3–13.
Matsuzuka, T., Rachakatla, R.S., Doi, C., Maurya, D.K., Ohta, N.,
Kawabata, A., Pyle, M.M., Pickel, L., Reischman, J., Marini, F.,
Troyer, D., Tamura, M., 2009. Human umbilical cord matrix-
derived stem cells expressing interferon-beta gene significantly
attenuate bronchioloalveolar carcinoma xenografts in SCID mice.
Lung Cancer 70, 28–36.
McArthur, H.L., Mahoney, K.M., Morris, P.G., Patil, S., Jacks, L.M.,
Howard, J., Norton, L., Hudis, C.A., 2011. Adjuvant
trastuzumab with chemotherapy is effective in women with
small, node-negative, HER2-positive breast cancer. Cancer
117, 5461–5468.
Nawa, A., Tanino, T., Luo, C., Iwaki, M., Kajiyama, H., Shibata, K.,
Yamamoto, E., Ino, K., Nishiyama, Y., Kikkawa, F., 2008. Gene
directed enzyme prodrug therapy for ovarian cancer: could
GDEPT become a promising treatment against ovarian cancer?
Anti Cancer Agents Med. Chem. 8, 232–239.
Niess, H., Bao, Q., Conrad, C., Zischek, C., Notohamiprodjo, M.,
Schwab, F., Schwarz, B., Huss, R., Jauch, K.W., Nelson, P.J.,
Bruns, C.J., 2011. Selective targeting of genetically engineered
mesenchymal stem cells to tumor stroma microenvironments
using tissue-specific suicide gene expression suppresses growth
of hepatocellular carcinoma. Ann. Surg. 254, 767–774 (discus-
sion 774–765).
Oie, S., Ono, M., Yano, H., Maruyama, Y., Terada, T., Yamada, Y.,
Ueno, T., Kojiro, M., Hirano, K., Kuwano, M., 2006. The up-
regulation of type I interferon receptor gene plays a key role in
hepatocellular carcinoma cells in the synergistic antiprolifera-
tive effect by 5-fluorouracil and interferon-alpha. Int. J. Oncol.
29, 1469–1478.
Pastorakova, A., Hlubinova, K., Altaner, C., 2006. Treatment of
human tumor cells by combine gene therapy harnessing
plasmids expressing human tumor necrosis factor alpha and
bacterial cytosine deaminase suicide gene. Neoplasma 53,
478–484.
Pestka, S., Krause, C.D., Walter, M.R., 2004. Interferons, interferon-
like cytokines, and their receptors. Immunol. Rev. 202, 8–32.
Piccart, M., 2003. The role of taxanes in the adjuvant treatment of
early stage breast cancer. Breast Cancer Res. Treat. 79 (Suppl.
1), S25–S34.
Qiao, J., Black, M.E., Caruso, M., 2000. Enhanced ganciclovir killing
and bystander effect of human tumor cells transduced with a
48 B.-R. Yi et al.retroviral vector carrying a herpes simplex virus thymidine
kinase gene mutant. Hum. Gene Ther. 11, 1569–1576.
Rosewicz, S., Detjen, K., Scholz, A., von Marschall, Z., 2004.
Interferon-alpha: regulatory effects on cell cycle and angiogen-
esis. Neuroendocrinology 80 (Suppl. 1), 85–93.
Shah, K., 2012. Mesenchymal stem cells engineered for cancer
therapy. Adv. Drug Deliv. Rev. 64, 739–748.
Sottini, A., Capra, R., Serana, F., Chiarini, M., Caimi, L., Imberti, L.,
2009. Interferon-beta therapy monitoring in multiple sclerosis
patients. Endocrinol. Metab. Immune Disord. Drug Targets 9, 14–28.
Thu, M.S., Najbauer, J., Kendall, S.E., Harutyunyan, I., Sangalang,
N., Gutova, M., Metz, M.Z., Garcia, E., Frank, R.T., Kim, S.U.,
Moats, R.A., Aboody, K.S., 2009. Iron labeling and pre-clinical
MRI visualization of therapeutic human neural stem cells in a
murine glioma model. PLoS One 4, e7218.
Uze, G., Monneron, D., 2007. IL-28 and IL-29: newcomers to the
interferon family. Biochimie 89, 729–734.
Vincent-Salomon, A., Thiery, J.P., 2003. Host microenvironment in
breast cancer development: epithelial-mesenchymal transition
in breast cancer development. Breast Cancer Res. 5, 101–106.
Vogel, K.J., Atchley, D.P., Erlichman, J., Broglio, K.R., Ready, K.J.,
Valero, V., Amos, C.I., Hortobagyi, G.N., Lu, K.H., Arun, B.,
2007. BRCA1 and BRCA2 genetic testing in Hispanic patients:
mutation prevalence and evaluation of the BRCAPRO risk
assessment model. J. Clin. Oncol. 25, 4635–4641.
Volate, S., Hudson, R.,Wang, D., Muga, S.,Wargovich, M., 2009. TJ-41
induces apoptosis and potentiates the apoptotic effects of 5-FU in
breast cancer cell lines. J. Oncol. 2009, 895381.
Wagner, T.C., Velichko, S., Chesney, S.K., Biroc, S., Harde, D.,
Vogel, D., Croze, E., 2004. Interferon receptor expression
regulates the antiproliferative effects of interferons on cancer
cells and solid tumors. Int. J. Cancer 111, 32–42.Wallace, J.A., Li, F., Leone, G., Ostrowski, M.C., 2011. Pten in the
breast tumor microenvironment: modeling tumor-stroma coevo-
lution. Cancer Res. 71, 1203–1207.
Yi, B.R., Kang, N.H., Hwang, K.A., Kim, S.U., Jeung, E.B., Choi,
K.C., 2011a. Antitumor therapeutic effects of cytosine deami-
nase and interferon-{beta} against endometrial cancer cells
using genetically engineered stem cells in vitro. Anticancer Res.
31, 2853–2861.
Yi, B.R., O, S.N., Kang, N.H., Hwang, K.A., Kim, S.U., Jeung, E.B.,
Kim, Y.B., Heo, G.J., Choi, K.C., 2011b. Genetically engineered
stem cells expressing cytosine deaminase and interferon-beta
migrate to human lung cancer cells and have potentially
therapeutic anti-tumor effects. Int. J. Oncol. 39, 833–839.
Yi, B.R., Hwang, K.A., Kang, N.H., Kim, S.U., Jeung, E.B., Kim, H.C.,
Choi, K.C., 2012. Synergistic effects of genetically engineered stem
cells expressing cytosine deaminase and interferon-beta via their
tumor tropism to selectively target human hepatocarcinoma cells.
Cancer Gene Ther. 19, 644–651.
Yoshiji, H., Kuriyama, S., Noguchi, R., Yoshii, J., Ikenaka, Y., Yanase,
K., Namisaki, T., Kitade, M., Yamazaki, M., Tsujinoue, H., Fukui,
H., 2005. Combination of interferon-beta and angiotensin-
converting enzyme inhibitor, perindopril, attenuates the murine
liver fibrosis development. Liver Int. 25, 153–161.
Zhao, D., Najbauer, J., Annala, A.J., Garcia, E., Metz, M.Z., Gutova,
M., Polewski, M.D., Gilchrist, M., Glackin, C.A., Kim, S.U.,
Aboody, K.S., 2012. Human neural stem cell tropism to
metastatic breast cancer. Stem Cells 30, 314–325.
Zoli, W., Ulivi, P., Tesei, A., Fabbri, F., Rosetti, M., Maltoni, R.,
Giunchi, D.C., Ricotti, L., Brigliadori, G., Vannini, I., Amadori,
D., 2005. Addition of 5-fluorouracil to doxorubicin-paclitaxel
sequence increases caspase-dependent apoptosis in breast
cancer cell lines. Breast Cancer Res. 7, R681–R689.
